Ignite Creation Date:
2024-05-05 @ 4:45 PM
Last Modification Date:
2024-10-26 @ 9:23 AM
Study NCT ID:
NCT00302159
Status:
COMPLETED
Last Update Posted:
2016-08-18
First Post:
2006-03-11
Brief Title:
Valproic Acid With Temozolomide and Radiation Therapy to Treat Brain Tumors
Sponsor:
National Cancer Institute NCI
Organization:
National Institutes of Health Clinical Center CC
Study Overview
Official Title:
A Phase II Clinical Trial of the Histone Deacetylase Inhibitor Valproic Acid in Combination With Temodar and Radiation Therapy in Patients With High Grade Gliomas Multi-Institutional Trial
Status:
COMPLETED
Status Verified Date:
2016-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Background
Radiation therapy with temozolomide an anti-cancer drug is standard therapy for treating brain tumors called glioblastomas
The drug valproic acid currently approved for treating seizures has been shown in laboratory tests to increase the radiosensitivity of glioma cells
Objectives
-To determine the effectiveness of adding valproic acid to standard treatment with radiation therapy and temozolomide for treating glioblastoma
Eligibility
-Patients 18 years of age and older with glioblastoma multiforme who have not been previously treated with chemotherapy of radiation
Design
This Phase II trial will enroll 41 patients
Patients will receive radiation therapy to the brain once a day Monday through Friday for 6 12 weeks
Patients will take temozolomide once a day by mouth Monday through Friday during the period of radiation treatment Starting 4 weeks after radiation therapy patients will take temozolomide once a day for 5 days every 28 days for a total of six cycles
Patients will receive valproic acid by mouth twice a day beginning 1 week prior to the first day of radiation therapy and continuing until the completion of chemotherapy and radiation therapy
Patients will have follow-up visits 1 month after completing therapy then every 3 months for 2 years and then every 6 months for 3 years Follow-up includes a physical examination blood tests and magnetic resonance imaging of the brain
Radiation therapy with temozolomide an anti-cancer drug is standard therapy for treating brain tumors called glioblastomas
The drug valproic acid currently approved for treating seizures has been shown in laboratory tests to increase the radiosensitivity of glioma cells
Objectives
-To determine the effectiveness of adding valproic acid to standard treatment with radiation therapy and temozolomide for treating glioblastoma
Eligibility
-Patients 18 years of age and older with glioblastoma multiforme who have not been previously treated with chemotherapy of radiation
Design
This Phase II trial will enroll 41 patients
Patients will receive radiation therapy to the brain once a day Monday through Friday for 6 12 weeks
Patients will take temozolomide once a day by mouth Monday through Friday during the period of radiation treatment Starting 4 weeks after radiation therapy patients will take temozolomide once a day for 5 days every 28 days for a total of six cycles
Patients will receive valproic acid by mouth twice a day beginning 1 week prior to the first day of radiation therapy and continuing until the completion of chemotherapy and radiation therapy
Patients will have follow-up visits 1 month after completing therapy then every 3 months for 2 years and then every 6 months for 3 years Follow-up includes a physical examination blood tests and magnetic resonance imaging of the brain
Detailed Description:
BACKGROUND
Histone deacetylase inhibitors HDACi have recently been shown to enhance the radiosensitivity of glioma cells both in vitro and in vivo
Valproic acid has also recently been demonstrated to be a potent HDAC
Valproic acid has a long clinical history in patients with and without brain tumors and is known to cross the blood-brain barrier However the use of valproic acid in combination with temozolomide and radiotherapy for patients with high-grade gliomas has never been tested
OBJECTIVES
-The primary measure of efficacy will be progression free survival and overall survival
ELIGIBILITY
Patients greater than 18 years old
Diagnosis glioblastoma multiforme
Eastern Cooperative Oncology Group ECOG performance status of 0 1 or 2
Patients who have not been previously treated with chemotherapy or radiation
DESIGN
This is a Phase II trial to determine the efficacy of valproic acid in combination with external beam radiation therapy and temozolomide in patients with high-grade gliomas
Patients will be treated with external beam radiation therapy in a standard manner with temozolomide given daily during the radiation The valproic acid will be administered daily beginning one week prior to the first day of irradiation and continuing until the completion of chemoradiation
We anticipate that accrual to this trial of 41 patients will take approximately 1 year
Histone deacetylase inhibitors HDACi have recently been shown to enhance the radiosensitivity of glioma cells both in vitro and in vivo
Valproic acid has also recently been demonstrated to be a potent HDAC
Valproic acid has a long clinical history in patients with and without brain tumors and is known to cross the blood-brain barrier However the use of valproic acid in combination with temozolomide and radiotherapy for patients with high-grade gliomas has never been tested
OBJECTIVES
-The primary measure of efficacy will be progression free survival and overall survival
ELIGIBILITY
Patients greater than 18 years old
Diagnosis glioblastoma multiforme
Eastern Cooperative Oncology Group ECOG performance status of 0 1 or 2
Patients who have not been previously treated with chemotherapy or radiation
DESIGN
This is a Phase II trial to determine the efficacy of valproic acid in combination with external beam radiation therapy and temozolomide in patients with high-grade gliomas
Patients will be treated with external beam radiation therapy in a standard manner with temozolomide given daily during the radiation The valproic acid will be administered daily beginning one week prior to the first day of irradiation and continuing until the completion of chemoradiation
We anticipate that accrual to this trial of 41 patients will take approximately 1 year
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 06-C-0112 | None | None | None |